298380.KQ Overview

Company Profile

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Related stocks

226950.KQ

226950.KQ • South Korea

117,300 KRW

1.84B USD 1Y +27.9%

141080.KQ

141080.KQ • South Korea

73,300 KRW

2.02B USD 1Y -51.9%

214450.KQ

214450.KQ • South Korea

302,500 KRW

2.35B USD 1Y -45%

0009K0.KQ

0009K0.KQ • South Korea

24,250 KRW

1.16B USD

145020.KQ

145020.KQ • South Korea

182,800 KRW

1.47B USD 1Y -36%

302440.KS

302440.KS • South Korea

36,750 KRW

2.15B USD 1Y -22.6%

9606.HK

9606.HK • China

182.7 HKD

2.13B USD 1Y -42.1%

0126Z0.KS

0126Z0.KS • South Korea

SAMSUNG EPIS HOLDINGS

340,500 KRW

6.32B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.ablbio.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

71.2% p.a.

Max Drawdown (5Y)

-80.5%

Sharpe Ratio (5Y)

0.26

Beta Factor

0.28

Size Class

Mega Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Unprofitable business model: The company is currently generating net losses.

🔴 High valuation risk: Avg P/E of 111.2 (Elevated multiple compression risk)

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Elevated Short-Term Volatility: 3Y volatility (79.0%) is noticeably higher than the 5Y average (71.2%).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (71.2% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -80.5% in the extended horizon.